Epstein–Barr virus (EBV)-associated lymphoproliferative diseases (LPDs) cover a wide range of lymphocytes disorders spanning B, T and natural killer cells. The classification of EBV-associated LPD is evolving. We report a case of a 63-year-old male patient with EBV-associated T/B cell LPD diagnosed by pathological biopsy of lymph nodes, which is a new type of EBVassociated LPD that has not been reported previously. Because of its rarity, standard treatment has not been established. This patient showed rapid remission of the disease after combination chemotherapy with rituximab, which provided evidence supporting the use of rituximab and chemotherapy combination in EBV-associated T/B cell LPD treatment.